#RNAtherapy
LightNews LightNews
norgenbiotek.bsky.social
🧬 RNA-based therapies are changing oncology.

circPSAP is showing promise as a marker for survival and drug resistance in multiple myeloma. Could targeting it lead to more effective treatments?

🔗 youtube.com/shorts/J0nvr...

#CancerResearch #RNAtherapy #Oncology
March 4, 2025 at 4:02 PM
sigtrans-sttt.bsky.social
Researchers use #Phosphoproteomics to define disease-specific pathways in phospholamban #Cardiomyopathy and show that #RNAtherapy can reverse key molecular defects associated with #CardiacDysfunction. @rug.nl
#STTT #OpenAccess: doi.org/10.1038/s413...
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy
May 30, 2026 at 12:45 PM
madeindenmark.bsky.social
Via Euronews: Gene therapy: The breakthrough that inspired Spider-Man | Euronews Tech Talks
www.euronews.com/2026/09/30/g...
#RNATherapy #RNA #GeneTherapy #SpiderMan #HowDoesItWork
Gene therapy: The breakthrough that inspired Spider-Man | Podcast
Although an inspiration for science fiction movies, gene therapy is real. Here is how it works and what could be improved about it.
www.euronews.com
October 4, 2026 at 2:22 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.
doi.org/10.1093/abt/...
#mab #biologics #antibodyoligonucleotideconjugate #aoc #rnatherapy #multispecificdrugs
September 11, 2026 at 6:36 PM
sparknify.bsky.social
🧬 This Taiwanese biotech startup is taking on one of medicine’s toughest challenges: fibrosis with a groundbreaking nucleic acid therapy.

Read: 👉 www.sparknify.com/post/this-ta...

#Biotech #Fibrosis #IPF #RNAtherapy #TaiwanStartups #Healthtech #Sparknify
July 14, 2025 at 2:44 PM
medchemexpress.bsky.social
🧬#Sefaxersen targets complement #FactorB mRNA, reducing FactorB and blocking the alternative pathway. Now in Phase3 IMAGINATION, this #RNAtherapy offers high specificity, long-acting effects, and potential disease-modifying benefits for kidney disease.
#Kidney #PrecisionMedicine
January 7, 2026 at 2:29 AM
catapultnetwork.bsky.social
#ICYMI, CPI — part of @hvmcatapult.bsky.social — announced last week that it is to host the £30 million UK RNA Biofoundry to help fast-track next-gen RNA therapies 🧬

🔗 https://loom.ly/Jt-T0OQ

#CatapultNetwork #RNAtherapy
September 1, 2025 at 9:00 AM
dengyuemedicine.bsky.social
Aquí tienes una versión más corta para X:

Solo el 5% de 7.000 enfermedades raras tiene tratamiento.
300M+ personas siguen esperando.

Las terapias de ARN están cambiando eso 🧬
El cambio ya empezó 🚀

#RareDiseases #RNATherapy #Biotech
March 17, 2026 at 7:19 AM
ssimoncellimwtc.bsky.social
7/7
RNatives is redefining what's possible in gene therapy.
By harnessing the power of RNA, they're turning the body's own mechanisms into medicine.

👉 Ready to see where this innovation leads?
#RNAtherapy #GeneRegulation #BiotechInnovation
June 6, 2025 at 7:03 AM
genewiz.bsky.social
Thank you for joining us at #PEGS2025! Catch us again at GENEWIZ Summer Camp June 9-13! 🏕️

Learn to build the perfect #plasmid, interpret #nanopore results, create an #RNATherapy, master #mulitomics, and plan your first #proteomics experiment!

Join us at the campfire: web.genewiz.com/summer-camp
May 19, 2025 at 4:08 PM
d2rmcgill.bsky.social
🔊#D2RProjectSpotlight: RNA therapy for Schinzel-Giedion Syndrome (SGS)

🧬Led by Carl Ernst at @mcgill.ca, this project aims to develop RNA therapy for SGS, a rare genetic disease affecting the brain & lungs

🔗Learn more: buff.ly/b4ugUp8
#RareDisease #RNATherapy
@mcgill-research.bsky.social
June 5, 2025 at 1:16 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Review Highlight -Antibody-oligonucleotide conjugates (AOCs): an emerging modality for precision RNA therapeutics
academic.oup.com/abt/advance-...
#biologics #antibodyoligonucleotideconjugate #aoc #rnatherapy #multispecificdrugs
Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics
Abstract. RNA-targeting therapeutics have enormous potential to precisely target disease-causing RNAs, extending beyond the traditional limits of “druggabi
academic.oup.com
June 5, 2026 at 10:30 AM
thecancersurvivorsclub.com
Scientists Create First-Ever Drug to Destroy Cancer’s “Immortality” RNA!
Researchers have developed a small molecule that targets and destroys TERRA RNA; helping halt tumour growth.
#CancerResearch #Oncology #MedicalBreakthrough #RNAtherapy #TCSC #Tumour

scitechdaily.com/scientists-c...
Scientists Create First-Ever Drug to Destroy Cancer’s “Immortality” RNA
A research team has unveiled a small molecule that hunts down a cancer-enabling RNA and quietly erases it. Researchers have designed a groundbreaking drug molecule capable of precisely eliminating TER...
scitechdaily.com
November 8, 2025 at 1:19 PM
thecancersurvivorsclub.com
Scientists have identified RNA molecule that selectively destroys hormone receptor-positive breast cancer cells and activates the immune system against them. Could be a game-changer for the most common form of breast cancer. #BreastCancer #RNAtherapy #TCSC
👉 www.linkedin.com/posts/medica...
New RNA Molecule Shows Promise for HR+ Breast Cancer Treatment | Medical Xpress posted on the topic | LinkedIn
A newly identified long noncoding RNA molecule shows promise as a targeted therapy for hormone receptor-positive (HR+) breast cancer, the most common form of the disease. This RNA-based approach demon...
www.linkedin.com
February 6, 2026 at 11:52 AM
sigtrans-sttt.bsky.social
This study identifies a distinct #Phosphoproteomic signature of PLN R14del #Cardiomyopathy involving cytoskeletal and contractile pathways, with PLN-targeted #RNAtherapy reversing key changes and reducing protein aggregation. @rug.nl

#CoverPage #STTT #OpenAccess: doi.org/10.1038/s413...
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy
August 13, 2026 at 12:15 PM
fdeiman.bsky.social
Proud to see our work on phospholamban (PLN) cardiomyopathy featured on the cover of Signal Transduction and Targeted Therapy.

doi.org/10.1038/s413...

#CardioSky #Cardiology #HeartFailure #PrecisionMedicine #RNATherapy #InheritedCardiomyopathy #OpenAccess
July 28, 2026 at 9:55 AM
sigtrans-sttt.bsky.social
Learn how #Phosphoproteomics guides precision therapy for phospholamban #Cardiomyopathy. This study shows that #RNAtherapy reverses disease-specific signaling changes, supporting a targeted approach for inherited #HeartDisease. @rug.nl

#STTT #OpenAccess: doi.org/10.1038/s413...
Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy
July 24, 2026 at 2:40 AM
kaluwu.bsky.social
Medical breakthrough

#GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 26, 2026 at 4:43 PM
kaluwu.bsky.social
Latest science breakthrough. #GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 12, 2026 at 9:28 PM
kaluwu.bsky.social
Building Life from Scratch

#GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 8:46 PM
kaluwu.bsky.social
The Race to Bring Back Extinct Species Accelerates

#GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 8:36 PM
kaluwu.bsky.social
Artificial Eggs Successfully Hatch Chicks #GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 8:25 PM
kaluwu.bsky.social
Personalized CRISPR Medicine Is Becoming Reality
#GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 8:18 PM
kaluwu.bsky.social
Eli Lilly signed a deal worth up to $1.9 billion with Ascidian Therapeutics to develop treatments for inherited kidney diseases using a new type of RNA exon-editing technology. #GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 8:12 PM
kaluwu.bsky.social
Eli Lilly signed a deal worth up to $1.9 billion with Ascidian Therapeutics to develop treatments for inherited kidney diseases using a new type of RNA exon-editing technology. #GeneEditing
#BiotechInnovation
#RNATherapy
#GeneticMedicine
#FutureOfHealthcare
June 3, 2026 at 7:53 PM